/
CLLS
$2.94+$0.11 (+3.89%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$284.7M
101M shares
52-week range
$1.42 – $5.48
37% from low
Exchange
NASDAQ
ADRC
Borrow rate
0.31%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-12.53
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $12.7M | $15.2M | $51.1M | $30.3M | $19.2M | $755.0K | $41.5M | $72.9M |
| Cost of revenue | $2.7M | $11.4M | $2.0M | $1.8M | $8.5M | $7.4M | $9.2M | $9.8M |
| Gross profit | $10.0M | $3.8M | $49.1M | $28.5M | $10.7M | −$6.7M | $32.3M | $63.2M |
| Gross margin | 78.5% | 25.0% | 96.2% | 93.9% | 55.7% | -882.6% | 77.9% | 86.6% |
| R&D | $76.6M | $92.0M | $77.0M | $117.8M | $97.5M | $87.6M | $90.5M | $93.5M |
| Operating income | −$105.1M | −$123.6M | −$42.3M | −$103.5M | −$89.7M | −$97.3M | −$59.6M | −$33.1M |
| EBITDA | −$93.8M | −$105.7M | −$43.3M | −$78.4M | −$76.4M | −$92.6M | −$9.5M | −$39.8M |
| Net income | −$78.7M | −$102.1M | −$81.1M | −$114.2M | −$106.1M | −$101.1M | −$36.8M | −$67.6M |
| Net margin | -618.1% | -672.1% | -158.8% | -376.3% | -553.6% | -13385.3% | -88.6% | -92.7% |
| EPS (diluted) | -1.93 | -2.14 | -1.71 | -1.93 | -2.33 | -1.77 | -0.41 | -0.68 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $61M | $-0.92 | $-1.26–$-0.74 | 6 |
| 2027 | $118M | $-0.74 | $-1.10–$-0.50 | 5 |
| 2028 | $73M | $-1.30 | $-2.51–$-0.36 | 2 |
| 2029 | $80M | $-1.46 | $-2.80–$-0.40 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Cellectis S.A. American Depositary Shares
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
www.cellectis.com- Employees
- 229
- IPO / List date
- Mar 25, 2015
Held by traders on TradeandTell
No one on the platform currently holds CLLS.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in CLLS as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded CLLS yet.
